Cervical cancer ranks as the 4 th leading cause of female cancer and cancer deaths in the world. More than 99% of cervical cancer cases are due to HPV infection. Vaccination can significantly reduce the number of HPVrelated cancers in the future. The next big step is to change the order of the tests, ie. cervical cells are first tested for HPV, and then analyzed under a microscope. The objective of our study was to define the incidence of 19 types of HPV in Bulgarian women attended for routine gynecologic examination, in order to obtain the molecularepidemiological spectrum of this infection in the context of the actual preventive programs. We have used the medium-high risk PapillomaStrip kit, based on the principle of reverse hybridization, in samples of 151 Bulgarian women. We detected the total frequency of 44.4% for HPV infection and higher frequency in younger age group (<30 years-47.5% and 30-40 years-50%) compared to > 40 years old women (28%). The most frequent HPV types from our study were HPV 45 and 52 (10.6%), HPV 66 (8.6%) and HPV 31 (8%). In PAPI/II it was HPV52 (11.3%), followed by HPV45 (10.5%) and HPV66 (8.3%). In PAPIII the most common was HPV16 (44.4%), followed by HPV 45, 31, 66 and 59 (each of 22.2%). We emphasized on the high frequency of HPV45 in our study, which is reported as one of the most frequent types in cervical cancer. In conclusion, HPV genotyping provides information on the carriage of high-risk types and increased attention to these patients. This is a valuable information for planning preventive programs in regard to choosing diagnostic tests and vaccination. Our results revealed the wide spectrum of HPV infection in Bulgarian women, as about 70% of infected patients carry high-risk HPV 45, 52, 31, 16 and 18.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.